ADHD Pharmacotherapy and Mortality in Individuals With ADHD.

Journal: JAMA

Volume: 331

Issue: 10

Year of Publication: 2024

Affiliated Institutions:  Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. Centre for Innovation in Mental Health-School of Psychology, Faculty of Environmental and Life Sciences, and Clinical and Experimental Sciences (CNS and Psychiatry), Faculty of Medicine, University of Southampton, Southampton, United Kingdom. School of medical sciences, Örebro University, Örebro, Sweden.

Abstract summary 

Attention-deficit/hyperactivity disorder (ADHD) is associated with increased risks of adverse health outcomes including premature death, but it is unclear whether ADHD pharmacotherapy influences the mortality risk.To investigate whether initiation of ADHD pharmacotherapy was associated with reduced mortality risk in individuals with ADHD.In an observational nationwide cohort study in Sweden applying the target trial emulation framework, we identified individuals aged 6 through 64 years with an incident diagnosis of ADHD from 2007 through 2018 and no ADHD medication dispensation prior to diagnosis. Follow-up started from ADHD diagnosis until death, emigration, 2 years after ADHD diagnosis, or December 31, 2020, whichever came first.ADHD medication initiation was defined as dispensing of medication within 3 months of diagnosis.We assessed all-cause mortality within 2 years of ADHD diagnosis, as well as natural-cause (eg, physical conditions) and unnatural-cause mortality (eg, unintentional injuries, suicide, and accidental poisonings).Of 148 578 individuals with ADHD (61 356 females [41.3%]), 84 204 (56.7%) initiated ADHD medication. The median age at diagnosis was 17.4 years (IQR, 11.6-29.1 years). The 2-year mortality risk was lower in the initiation treatment strategy group (39.1 per 10 000 individuals) than in the noninitiation treatment strategy group (48.1 per 10 000 individuals), with a risk difference of -8.9 per 10 000 individuals (95% CI, -17.3 to -0.6). ADHD medication initiation was associated with significantly lower rate of all-cause mortality (hazard ratio [HR], 0.79; 95% CI, 0.70 to 0.88) and unnatural-cause mortality (2-year mortality risk, 25.9 per 10 000 individuals vs 33.3 per 10 000 individuals; risk difference, -7.4 per 10 000 individuals; 95% CI, -14.2 to -0.5; HR, 0.75; 95% CI, 0.66 to 0.86), but not natural-cause mortality (2-year mortality risk, 13.1 per 10 000 individuals vs 14.7 per 10 000 individuals; risk difference, -1.6 per 10 000 individuals; 95% CI, -6.4 to 3.2; HR, 0.86; 95% CI, 0.71 to 1.05).Among individuals diagnosed with ADHD, medication initiation was associated with significantly lower all-cause mortality, particularly for death due to unnatural causes.

Authors & Co-authors:  Li Zhu Zhang Kuja-Halkola D'Onofrio Brikell Lichtenstein Cortese Larsson Chang

Study Outcome 

Source Link: Visit source

Statistics
Citations :  Faraone SV, Banaschewski T, Coghill D, et al. . The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder. Neurosci Biobehav Rev. 2021;128:789-818. doi:10.1016/j.neubiorev.2021.01.022
Authors :  10
Identifiers
Doi : 10.1001/jama.2024.0851
SSN : 1538-3598
Study Population
Females
Mesh Terms
Adolescent
Other Terms
Study Design
Cohort Study
Study Approach
Country of Study
Publication Country
United States